Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (MOMENTUM), pemvidutide demonstrated up to 15.6% weight loss at 48 weeks with notable preservation of lean body mass — a differentiating feature compared to other weight loss drugs where significant muscle loss is a concern.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and food intake. Glucagon activation increases energy expenditure, promotes fat oxidation, and may help preserve lean mass during weight loss by shifting energy substrate utilization toward fat rather than protein catabolism.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Lean mass preservation during weight loss
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- GI side effects (nausea, diarrhea)
- Still in clinical trials — full safety profile not established
- Potential blood sugar effects
- Injection site reactions
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
Phase 2 completed (MOMENTUM trial). Phase 2b for MASH (IMPACT trial) ongoing. Altimmune reported 15.6% weight loss at 48 weeks with lean mass preservation. Phase 3 planning underway. The lean mass preservation claim is a key differentiator if confirmed in larger trials.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
- Pemvidutide Phase 2 MOMENTUM trial results
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.